Since 1989, Sigma-Tau Pharmaceuticals products have been focused on rare diseases, including kidney disease, certain genetic disorders and cancers.

Sigma-Tau Pharmaceuticals

Sigma-Tau Pharmaceuticals, Inc. is a U.S.-based, wholly owned subsidiary of the sigma-tau Group, and is dedicated solely to the global development and commercialization of medicines for patients with rare diseases. Sigma-Tau Pharmaceuticals, Inc. is based in Gaithersburg, Maryland.  Since 1989, the company’s products have been focused on rare diseases, including kidney disease, certain genetic disorders and cancers.  With more than 7,000 identified rare diseases that affect approximately 25 million patients in the Unites States, Sigma-Tau Pharmaceuticals places its considerable scientific resources behind the development and commercialization of compounds that benefit the few.  The company has a substantial development program focused on transplants, cancer, inherited genetic disorders, malaria, and other areas of unmet medical need.  For more information about the company, visit www.sigmatau.com.